| 摘要 |
<p>It is intended to provide a novel examination method for accurately judging the efficacy of a treatment with a carcinostatic agent in the administration of the carcinostatic agent targeting a tumor-associated factor receptor. In judging the efficacy of a carcinostatic agent trastuzumab (Herceptin<TM>), it is found out meaningful to examine the expression of MUC4 which is a substance interacting with HER2/c-erbB-2 belonging to the epithelial cell growth factor receptor family on the surface of a cell membrane and/or in a cell membrane. Based on this finding, there has been established the significance of a search for the expression of an intracellular ligand to a tumor-associated factor receptor as an examination method before the initiation of a treatment with a carcinostatic agent targeting the receptor for treating various types of cancer.</p> |
